TY - JOUR
T1 - Recurrent and fixed neutrophilic dermatosis associated with dasatinib
AU - Bergman, Joel C.
AU - Ly, Thai Yen
AU - Keating, Margaret Mary
AU - Hull, Peter R.
N1 - Publisher Copyright:
© The Author(s) 2018.
PY - 2018/5/1
Y1 - 2018/5/1
N2 - Background: Dasatinib is a tyrosine kinase inhibitor indicated for the treatment of chronic myeloid leukemia (CML). Skin rashes are common, occurring in about a quarter of patients treated, and are generally mild. The commonest rash is a keratosis pilaris-like eruption. A neutrophilic dermatosis has rarely been reported. Objective: We report a patient whose CML was successfully treated with dasatinib and who several years later developed episodes of a neutrophilic dermatosis recurring at the same sites. Conclusion: This report extends the clinical spectrum of neutrophilic dermatoses to include dasatinib-induced recurrent and fixed erythematous plaques.
AB - Background: Dasatinib is a tyrosine kinase inhibitor indicated for the treatment of chronic myeloid leukemia (CML). Skin rashes are common, occurring in about a quarter of patients treated, and are generally mild. The commonest rash is a keratosis pilaris-like eruption. A neutrophilic dermatosis has rarely been reported. Objective: We report a patient whose CML was successfully treated with dasatinib and who several years later developed episodes of a neutrophilic dermatosis recurring at the same sites. Conclusion: This report extends the clinical spectrum of neutrophilic dermatoses to include dasatinib-induced recurrent and fixed erythematous plaques.
UR - http://www.scopus.com/inward/record.url?scp=85047377200&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85047377200&partnerID=8YFLogxK
U2 - 10.1177/1203475418775663
DO - 10.1177/1203475418775663
M3 - Article
C2 - 29754527
AN - SCOPUS:85047377200
SN - 1203-4754
VL - 22
SP - 621
EP - 623
JO - Journal of Cutaneous Medicine and Surgery
JF - Journal of Cutaneous Medicine and Surgery
IS - 6
ER -